Simeone emphasized the need to accurately determine which patients are at increased risk of developing disease, whether the risk be hereditary or otherwise. The PRECEDE Consortium, which is assembling investigators, researchers, and cancer centers, seeks to address several unanswered questions: Who is most at risk? What does this risk look like? How can these challenges be addressed? Read more . . .
In order to improve survival for patients with pancreatic cancer, developments need to be made in early detection, although progress has been slow due to a lack of unification; however, the creation of the Pancreatic Cancer Early Detection (PRECEDE) Consortium may help to help foster collaboration in the pancreatic space and possibly save lives, according to Diane Simeone, MD.